(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 December 2015 (10.12.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/185584 A1

(51) International Patent Classification:
C07K 7/16 (2006.01) *A61K 38/08* (2006.01)

(21) International Application Number:
PCT/EP2015/062314

(22) International Filing Date:
3 June 2015 (03.06.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
14171440.2 6 June 2014 (06.06.2014) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road, 8th Floor, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BISSANTZ, Caterina**; 3, rue de Palmrain, F-68128 Village-Neuf (FR). **BLEICHER, Konrad**; Reichsgrafenstrasse 16, 79102 Freiburg (DE). **CHAKRABORTY, Kanchan**; c/o Ajoy Chakraborty, Sarat Pally Post Office - India, Dist.-West Midnapur PIN, West Bengal 721 305 (IN). **GRUNDSCHOBER, Christophe**; Landskronstrasse 18, CH-4118 Rodersdorf (CH). **SAHA, Goutam**; 1167 Rabindranagar Laskarpur, Kolkata, West Bengal 700 153 (IN).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2015/185584 A1

(54) Title: PEPTIDES AS OXYTOCIN AGONISTS



(I)

(57) Abstract: The invention relates to compounds of formula (I) wherein R^1 is hydrogen, lower alkyl, -CH_2-cycloalkyl or cycloalkyl; R^2 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy or R^1 and R^2 may form together with the N and C atom to which they are attached a pyrrolidine ring optionally substituted by one or two F-atoms or by hydroxy, or may form an azetidine or a piperidine ring; R^3 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy, -$(CH_2)_oNH_2$, benzyl optionally substituted by hydroxy, phenyl, -CH_2-cycloalkyl or cycloalkyl; $R^{3'}$ is hydrogen or lower alkyl; n is 1; m is 0 or 1; o is 1 to 4; or to pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawel, drug addiction and for the treatment of Prader-Willi Syndrom.